Corbus Pharms

CRBP NASDAQ
7.30
+0.03
+0.41%
After Hours: 7.25 -0.05 -0.68% 17:23 05/24 EDT
Open
7.30
Prev Close
7.27
High
7.51
Low
7.15
Volume
1.08M
Avg Vol (3M)
1.54M
52 Week High
9.11
52 Week Low
4.500
% Turnover
1.67%
Market Cap
470.52M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
MORE >

Recently

Name
Price
%Change